JP2015528509A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528509A5 JP2015528509A5 JP2015532108A JP2015532108A JP2015528509A5 JP 2015528509 A5 JP2015528509 A5 JP 2015528509A5 JP 2015532108 A JP2015532108 A JP 2015532108A JP 2015532108 A JP2015532108 A JP 2015532108A JP 2015528509 A5 JP2015528509 A5 JP 2015528509A5
- Authority
- JP
- Japan
- Prior art keywords
- integer
- composition
- moiety
- eye
- sulfonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000412 dendrimer Substances 0.000 claims description 18
- 229920000736 dendritic polymer Polymers 0.000 claims description 18
- 229920002521 macromolecule Polymers 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- 150000003871 sulfonates Chemical class 0.000 claims description 6
- 150000003460 sulfonic acids Chemical class 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims 19
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 11
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 11
- 108010039918 Polylysine Proteins 0.000 claims 7
- 229920000656 polylysine Polymers 0.000 claims 7
- 230000000813 microbial effect Effects 0.000 claims 6
- 241000701161 unidentified adenovirus Species 0.000 claims 4
- 206010010755 Conjunctivitis viral Diseases 0.000 claims 3
- 208000005914 Viral Conjunctivitis Diseases 0.000 claims 3
- 239000000882 contact lens solution Substances 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 2
- 201000007032 bacterial conjunctivitis Diseases 0.000 claims 2
- 230000001954 sterilising effect Effects 0.000 claims 2
- 238000004659 sterilization and disinfection Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000034579 Acute haemorrhagic conjunctivitis Diseases 0.000 claims 1
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 241000606790 Haemophilus Species 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010034960 Photophobia Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 206010042674 Swelling Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000006476 shipyard eye Diseases 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 7
- HJSJTXDVLAQOMA-UHFFFAOYSA-N CCCC(NC(C)(C)CS(O)(=O)=O)=O Chemical compound CCCC(NC(C)(C)CS(O)(=O)=O)=O HJSJTXDVLAQOMA-UHFFFAOYSA-N 0.000 description 5
- ZVZNQZHTMBIDJH-UHFFFAOYSA-N CC(CCC(NCC[S](C)(O)(=O)=O)=O)=O Chemical compound CC(CCC(NCC[S](C)(O)(=O)=O)=O)=O ZVZNQZHTMBIDJH-UHFFFAOYSA-N 0.000 description 3
- QPUYECUOLPXSFR-UHFFFAOYSA-N Cc1c(cccc2)c2ccc1 Chemical compound Cc1c(cccc2)c2ccc1 QPUYECUOLPXSFR-UHFFFAOYSA-N 0.000 description 3
- KWHYAIHZUQICHA-UHFFFAOYSA-N CC(CCC(NCCS(O)(=O)=O)=O)=O Chemical compound CC(CCC(NCCS(O)(=O)=O)=O)=O KWHYAIHZUQICHA-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- DNLDMOAFPACEFD-UHFFFAOYSA-N CC(C)(CS(O)(=O)=O)NC(CC=C)=O Chemical compound CC(C)(CS(O)(=O)=O)NC(CC=C)=O DNLDMOAFPACEFD-UHFFFAOYSA-N 0.000 description 1
- JJFZQNVFWVBLTQ-UHFFFAOYSA-N CCCC(NC(C)(C)CS(O)(=O)=O)=C Chemical compound CCCC(NC(C)(C)CS(O)(=O)=O)=C JJFZQNVFWVBLTQ-UHFFFAOYSA-N 0.000 description 1
- AKCVWFRALJPANX-UHFFFAOYSA-N CCCCC(NCCC)=O Chemical compound CCCCC(NCCC)=O AKCVWFRALJPANX-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261700714P | 2012-09-13 | 2012-09-13 | |
| US61/700,714 | 2012-09-13 | ||
| PCT/US2013/059810 WO2014043576A1 (en) | 2012-09-13 | 2013-09-13 | Method of treatment or prophylaxis of infections of the eye |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018191652A Division JP6766114B2 (ja) | 2012-09-13 | 2018-10-10 | 眼の感染症の治療または予防方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528509A JP2015528509A (ja) | 2015-09-28 |
| JP2015528509A5 true JP2015528509A5 (enExample) | 2018-01-11 |
| JP6419701B2 JP6419701B2 (ja) | 2018-11-07 |
Family
ID=50278734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532108A Active JP6419701B2 (ja) | 2012-09-13 | 2013-09-13 | 眼の感染症の治療または予防方法 |
| JP2018191652A Active JP6766114B2 (ja) | 2012-09-13 | 2018-10-10 | 眼の感染症の治療または予防方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018191652A Active JP6766114B2 (ja) | 2012-09-13 | 2018-10-10 | 眼の感染症の治療または予防方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10149885B2 (enExample) |
| EP (1) | EP2895161B1 (enExample) |
| JP (2) | JP6419701B2 (enExample) |
| CN (2) | CN108452316B (enExample) |
| CA (1) | CA2884897C (enExample) |
| DK (1) | DK2895161T3 (enExample) |
| ES (1) | ES2633778T3 (enExample) |
| IN (1) | IN2015DN02233A (enExample) |
| WO (1) | WO2014043576A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009008006A2 (en) * | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
| RU2667118C1 (ru) * | 2017-11-15 | 2018-09-14 | Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" | Универсальное средство в виде мази для комплексного лечения глазных болезней животных и способ его получения |
| CN110664757B (zh) * | 2018-11-19 | 2022-08-02 | 成都瑞沐生物医药科技有限公司 | 纳米晶滴眼剂、其制备方法及其应用 |
| JP7869752B2 (ja) * | 2020-04-15 | 2026-06-03 | スターファーマ・ピーティーワイ・リミテッド | コロナウイルス及び／又は呼吸器合胞体ウイルス感染症の予防の方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM623994A0 (en) | 1994-06-15 | 1994-07-07 | Biomolecular Research Institute Limited | Antiviral dendrimers |
| EP1096934B1 (en) | 1998-07-14 | 2005-09-21 | Pharmacia & Upjohn Company LLC | Oxazolidinones to treat eye infections |
| AUPP584298A0 (en) * | 1998-09-14 | 1998-10-08 | Starpharma Limited | Antimicrobial and antiparasitic agents |
| AUPR412801A0 (en) * | 2001-03-30 | 2001-05-03 | Starpharma Limited | Agent for the prevention and treatment of sexually transmitted disease s - I |
| WO2005007223A2 (en) * | 2003-07-16 | 2005-01-27 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
| DK1755616T3 (da) * | 2004-04-08 | 2013-11-25 | Eye Co Pty Ltd | Behandling af ekssudativ retinopati med mineralkortikoider |
| JP5213718B2 (ja) | 2005-10-18 | 2013-06-19 | スターファーマ・プロプライエタリー・リミテッド | 殺微生物性デンドリマー組成物のデリバリーシステム |
| HUE031341T2 (hu) * | 2005-10-25 | 2017-07-28 | Starpharma Pty Ltd | Ellenõrzött sztöchiometriájú makromolekuláris vegyületek |
| US8568790B2 (en) * | 2006-05-31 | 2013-10-29 | Medihoney Pty Ltd. | Medicinal compositions containing honey |
| EP2214646B1 (en) | 2007-10-05 | 2021-06-23 | Wayne State University | Dendrimers for sustained release of compounds |
| EP2398499B1 (en) * | 2009-02-18 | 2017-09-06 | Eyeon Particle Sciences LLC | Bi-functional co-polymer use for ophthalmic and other topical and local applications |
| CA2765919C (en) * | 2009-07-07 | 2017-07-18 | Adenovir Pharma Ab | New antiviral compounds useful for the treatment or the prevention of epidemic keratoconjonctivitis |
| HUE047170T2 (hu) | 2011-05-16 | 2020-04-28 | Starpharma Pty Ltd | Bakteriális vaginózis kezelési vagy megelõzési módszere |
-
2013
- 2013-09-13 WO PCT/US2013/059810 patent/WO2014043576A1/en not_active Ceased
- 2013-09-13 IN IN2233DEN2015 patent/IN2015DN02233A/en unknown
- 2013-09-13 CN CN201810557127.1A patent/CN108452316B/zh active Active
- 2013-09-13 US US14/427,970 patent/US10149885B2/en active Active
- 2013-09-13 ES ES13837849.2T patent/ES2633778T3/es active Active
- 2013-09-13 CN CN201380059141.4A patent/CN105007910B/zh active Active
- 2013-09-13 CA CA2884897A patent/CA2884897C/en active Active
- 2013-09-13 JP JP2015532108A patent/JP6419701B2/ja active Active
- 2013-09-13 DK DK13837849.2T patent/DK2895161T3/en active
- 2013-09-13 EP EP13837849.2A patent/EP2895161B1/en active Active
-
2018
- 2018-10-10 JP JP2018191652A patent/JP6766114B2/ja active Active
- 2018-11-02 US US16/179,384 patent/US11219691B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pandey et al. | Potential of stimuli-responsive in situ gel system for sustained ocular drug delivery: Recent progress and contemporary research | |
| TWI624263B (zh) | 胺官能性聚醯胺 | |
| ES2394130T3 (es) | Composiciones y métodos para tratar infecciones vaginales y biopelículas vaginales patógenas | |
| US20230128449A1 (en) | Silicate containing compositions and methods of treatment | |
| JP2014516954A5 (enExample) | ||
| TW201143783A (en) | Non-irritating ophthalmic povidone-iodine compositions | |
| JP2013520405A5 (enExample) | ||
| CN105246457B (zh) | 局部氨苯砜和氨苯砜/阿达帕林组合物及其使用方法 | |
| ES2449340T3 (es) | Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales | |
| EP3390367A1 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
| CA3019769C (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| TW200816994A (en) | Compositions and methods for the treatment of mucormycosis and other fungal diseases | |
| CN103687601B (zh) | 治疗或预防细菌性阴道病的方法 | |
| JP2014501768A5 (enExample) | ||
| JP6766114B2 (ja) | 眼の感染症の治療または予防方法 | |
| CN115624562A (zh) | 黄芩苷在制备治疗对免疫检查点抑制剂无应答/超进展的肿瘤的药物中的应用 | |
| JP2010506855A5 (enExample) | ||
| TWI482632B (zh) | 醫藥用載體及使用該載體的藥物結構 | |
| TW201625277A (zh) | 角結膜障礙治療劑 | |
| US20050227949A1 (en) | Compositions and methods for treatment of viral and bacterial infections | |
| ES2273872T3 (es) | Gatifloxacino como inhibidor de la produccion de citoquinas. | |
| JP2011121983A (ja) | 粘膜の疾患および障害の予防および処置のための液体製剤 | |
| CN101998856A (zh) | 锌/甲氧苄啶结合治疗 | |
| Sarma | Klebsiella ozaenae splenic abscess following odontogenic infection in a girl with sickle cell disease | |
| CA3111571A1 (en) | Infection-induced endothelial amyloid compositions as antimicrobials |